Switch theme
Sign up to access all valuation multiples
ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.
1999
22
Last FY Revenue $0.6M
Last FY EBITDA $7.7M
$158M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, ToolGen achieved revenue of $0.6M and an EBITDA of $7.7M.
ToolGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ToolGen valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.6M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 76% | XXX | XXX | XXX |
| EBITDA | XXX | $7.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 1195% | XXX | XXX | XXX |
| EBIT | XXX | -$15.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | -2446% | XXX | XXX | XXX |
| Net Profit | XXX | $4.5M | XXX | XXX | XXX |
| Net Margin | XXX | 699% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ToolGen's stock price is KRW 31250 (or $23).
ToolGen has current market cap of KRW 248B (or $180M), and EV of KRW 217B (or $158M).
See ToolGen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $158M | $180M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ToolGen has market cap of $180M and EV of $158M.
ToolGen's trades at 243.6x EV/Revenue multiple, and 20.4x EV/EBITDA.
Equity research analysts estimate ToolGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ToolGen's P/E ratio is not available.
See valuation multiples for ToolGen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $180M | XXX | $180M | XXX | XXX | XXX |
| EV (current) | $158M | XXX | $158M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 243.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 20.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -10.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 39.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialToolGen's revenue per employee in the last FY averaged $29K, while opex per employee averaged $0.7M for the same period.
ToolGen's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ToolGen's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ToolGen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 1195% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $29K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 991% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 768% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2522% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ToolGen acquired XXX companies to date.
Last acquisition by ToolGen was XXXXXXXX, XXXXX XXXXX XXXXXX . ToolGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ToolGen founded? | ToolGen was founded in 1999. |
| Where is ToolGen headquartered? | ToolGen is headquartered in South Korea. |
| How many employees does ToolGen have? | As of today, ToolGen has 22 employees. |
| Is ToolGen publicy listed? | Yes, ToolGen is a public company listed on KRX. |
| What is the stock symbol of ToolGen? | ToolGen trades under 199800 ticker. |
| When did ToolGen go public? | ToolGen went public in 2014. |
| Who are competitors of ToolGen? | Similar companies to ToolGen include e.g. EZZ Life Science, Epigenomics, 4basebio, Genus. |
| What is the current market cap of ToolGen? | ToolGen's current market cap is $180M |
| Is ToolGen profitable? | Yes, ToolGen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
